Ozempic Class Action Reveals Dangerous Side Effects

This episode dives into the billion-dollar Ozempic class action lawsuit, revealing how confusion over brand-name drugs versus compounded versions raises critical questions about liability, FDA guidelines, and patient safety. We explain the risks tied to GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro, including side effects such as gastroparesis, gallbladder issues, and even sudden blindness. The episode highlights the gray areas of off-label use, physician responsibility, and compounding pharmacy practices, underscoring why this case could reshape perceptions of drug safety and pharmaceutical accountability.